Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Works matching IS 03125963 AND DT 2010 AND VI 49 AND IP 9
Results: 6
1
2
Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 9, p. 619, doi. 10.2165/11533760-000000000-00000
- Publication type:
- Article
3
Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 9, p. 607, doi. 10.2165/11534330-000000000-00000
- Publication type:
- Article
4
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 9, p. 589, doi. 10.2165/11536600-000000000-00000
- Publication type:
- Article
5
Dipeptidylpeptitase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 9, p. 573, doi. 10.2165/11532980-000000000-00000
- Publication type:
- Article
6
Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 9, p. 567, doi. 10.2165/11532960-000000000-00000
- Publication type:
- Article